Linderman, George C. http://orcid.org/0000-0002-0074-0346
Zhao, Jun
Roulis, Manolis http://orcid.org/0000-0002-6898-3547
Bielecki, Piotr http://orcid.org/0000-0002-5609-1066
Flavell, Richard A. http://orcid.org/0000-0003-4461-0778
Nadler, Boaz http://orcid.org/0000-0002-9777-4576
Kluger, Yuval http://orcid.org/0000-0002-3035-071X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (F30HG010102, R01HG008383)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01GM131642, R01GM135928)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (UM1DA051410)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50CA121974)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute
Article History
Received: 10 February 2020
Accepted: 30 November 2021
First Online: 11 January 2022
Competing interests
: R.A.F. is a consultant for GlaxoSmithKline and Zai Lab Ltd. P.B. is an equity holder in Celsius Therapeutics. The remaining authors declare no competing interests.